David J. Paterson | |
---|---|
Born | 21 April 1959 |
Awards | Rolleston Memorial Prize (1989) GL Brown Prize Lecture (2000) Carl Ludwig Distinguished Lecturer (2018) |
Academic background | |
Alma mater | University of Otago University of Western Australia University of Oxford |
Academic work | |
Sub-discipline | Cardiac neurobiology |
David James Paterson MAE Hon FRSNZ [1] is a New Zealand-born British physiologist and academic. He is a Fellow of Merton College,Oxford at the University of Oxford. He is also the Head of the Department of Physiology,Anatomy and Genetics at Oxford,and immediate Past President of The Physiological Society of the United Kingdom and Republic of Ireland. [2] Paterson is best known for his work in cardiac neurobiology,linking the nervous system to heart rhythm,which was featured in the 2012 BBC Four documentary Heart v Mind:What Makes Us Human?,and associated interviews on RNZ National Science programme Heart v Mind. [3] In 2018 he co-authored with Neil Herring the text book Levick's Introduction to Cardiovascular Physiology,6th edition. [4]
Paterson was born in Timaru,New Zealand on 21 April 1959. He attended Otago Boys' High School and the University of Otago before training as a secondary teacher. He was awarded a Master of Science degree in 1985 from the University of Western Australia,and won a Hackett scholarship to New College,Oxford and completed a DPhil thesis,in 1989,on the control of breathing and chemoreception from the University Laboratory of Physiology. In 2005,he was awarded a Doctor of Science degree from the University of Western Australia.[ citation needed ]
Paterson was elected to a Junior Research Fellowship at Christ Church,Oxford from 1988 to 1991. He switched fields when appointed to a British Heart Foundation Lectureship in 1991 in cardiovascular physiology at Oxford. In 1994,he was made a University Lecturer in association with a Tutorial Fellowship at Merton College,Oxford,and then,in 1998,a Reader in Physiology and in 2002,Professor of Cardiovascular Physiology. In 2016,Paterson was appointed Head of the Department of Physiology,Anatomy and Genetics at Oxford,and in 2021 unveiled the department's Statement of Inclusion in conjunction with the Equality,Diversity and Inclusion Committee. In 2018 he was made President-elect of The Physiological Society to serve as president in 2020–22. [2] Paterson was the Editor-in-Chief of Experimental Physiology from 2006 to 2011 and of The Journal of Physiology from 2011 to 2016. [5] He is a Fellow of the Royal Society of Biology and in 2014 was elected an Honorary Fellow of The Royal Society of New Zealand. In 2016 he delivered the Brookhart Award Lecture in Oregon. He was elected as an inaugural Fellow of The Physiological Society in 2017. In 2018 he delivered the Carl Ludwig Distinguished Lecture for the American Physiological Society at Experimental Biology. In 2019 he was elected a Fellow of the American Physiological Society. In 2020 he was appointed as a Core Member of the UKRI-BBSRC Bioscience Advisory Panel for an Integrated Understanding of Health Strategy and in 2021 elected a Member of Academia Europaea During 2021-22 he Chaired the controversial 10 year review of Oxford's Employer-Justified Retirement Age (EJRA). The group made wide-ranging recommendations and concluded that the EJRA was justified for some academic grades based on one of the university's legitimate Aims regarding equality and intergeneration fairness. All recommendations were accepted by Council and Congregation. [6] [7] In 2023 Paterson was made an Honorary Fellow of The Physiological Society and received an Honorary degree from the University of Western Australia (Hon DUniv in Medical Sciences). In 2024 he was elected to the Academy of Fellows of the International Union of Physiological Sciences Fellows of IUPS Academy 2024
Paterson is best known for his studies on potassium, [8] chemoreception [9] and respiratory control,and more recently for his discovery linking peptides and the gaseous messenger nitric oxide to cyclic nucleotide coupled cardiac autonomic neurotransmission. His work has contributed to the understanding of how the nervous system modulates cardiac excitability in health and disease. [10] Paterson leads a research team in the area of cardiac neurobiology. They are interested in how both branches of the cardiac autonomic nervous system communicate at the end organ level and established that oxidative stress plays a major role in uncoupling pre-synaptic and post synaptic signalling. The endogenous gas nitric oxide is a key intermediary in cardiac inter/intracellular signalling,where it regulates several ion channels that control cardiac excitability. His group has developed methods for targeting the enzyme involved in making nitric oxide-cGMP using a gene transfer approach involving cell specific viral vectors and FRET sensors to study the physiology of this messenger in normal and diseased hearts. [11] [12]
The sympathetic nervous system is one of the three divisions of the autonomic nervous system,the others being the parasympathetic nervous system and the enteric nervous system. The enteric nervous system is sometimes considered part of the autonomic nervous system,and sometimes considered an independent system.
Robert Francis Furchgott was a Nobel Prize-winning American biochemist who contributed to the discovery of nitric oxide as a transient cellular signal in mammalian systems.
Vasodilation,also known as vasorelaxation,is the widening of blood vessels. It results from relaxation of smooth muscle cells within the vessel walls,in particular in the large veins,large arteries,and smaller arterioles. Blood vessel walls are composed of endothelial tissue and a basal membrane lining the lumen of the vessel,concentric smooth muscle layers on top of endothelial tissue,and an adventitia over the smooth muscle layers. Relaxation of the smooth muscle layer allows the blood vessel to dilate,as it is held in a semi-constricted state by sympathetic nervous system activity. Vasodilation is the opposite of vasoconstriction,which is the narrowing of blood vessels.
A neuroeffector junction is a site where a motor neuron releases a neurotransmitter to affect a target—non-neuronal—cell. This junction functions like a synapse. However,unlike most neurons,somatic efferent motor neurons innervate skeletal muscle,and are always excitatory. Visceral efferent neurons innervate smooth muscle,cardiac muscle,and glands,and have the ability to be either excitatory or inhibitory in function. Neuroeffector junctions are known as neuromuscular junctions when the target cell is a muscle fiber.
The Endothelium-derived relaxing factor (EDRF) is a strong vasodilator produced by cardiac endothelial cells in response to stress signals such as high levels of ADP accumulation or hypoxia. Robert F. Furchgott is widely recognised for this discovery,even going so far as to be a co-recipient of the 1998 Nobel Prize in Medicine with his colleagues Louis J. Ignarro and Ferid Murad. Nitric oxide (NO) is a key component in any EDRF as these compounds either include NO or are structurally in the form of NO.
Nitric oxide synthases (NOSs) are a family of enzymes catalyzing the production of nitric oxide (NO) from L-arginine. NO is an important cellular signaling molecule. It helps modulate vascular tone,insulin secretion,airway tone,and peristalsis,and is involved in angiogenesis and neural development. It may function as a retrograde neurotransmitter. Nitric oxide is mediated in mammals by the calcium-calmodulin controlled isoenzymes eNOS and nNOS. The inducible isoform,iNOS,involved in immune response,binds calmodulin at physiologically relevant concentrations,and produces NO as an immune defense mechanism,as NO is a free radical with an unpaired electron. It is the proximate cause of septic shock and may function in autoimmune disease.
Cyclic guanosine monophosphate-specific phosphodiesterase type 5 is an enzyme from the phosphodiesterase class. It is found in various tissues,most prominently the corpus cavernosum and the retina. It has also been recently discovered to play a vital role in the cardiovascular system.
Sir Salvador Enrique Moncada Seidner,FRS,FRCP,FMedSci is a Honduran-British pharmacologist and professor. He is currently Research Domain Director for Cancer at the University of Manchester.
Louis Joseph Ignarro is an American pharmacologist. For demonstrating the signaling properties of nitric oxide,he was co-recipient of the 1998 Nobel Prize in Physiology or Medicine with Robert F. Furchgott and Ferid Murad.
Denis Noble is a British physiologist and biologist who held the Burdon Sanderson Chair of Cardiovascular Physiology at the University of Oxford from 1984 to 2004 and was appointed Professor Emeritus and co-Director of Computational Physiology. He is one of the pioneers of systems biology and developed the first viable mathematical model of the working heart in 1960. Noble established The Third Way of Evolution (TWE) project with James A. Shapiro which predicts that the entire framework of the modern synthesis will be replaced.
The pacemaker current is an electric current in the heart that flows through the HCN channel or pacemaker channel. Such channels are important parts of the electrical conduction system of the heart and form a component of the natural pacemaker.
Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 is a protein that in humans is encoded by the HCN4 gene.
Biological functions of nitric oxide are roles that nitric oxide plays within biology.
Vagotonia is the state of the autonomic nervous system in which there is increased parasympathetic input through the vagus nerve,or the equilibrium between the sympathetic and parasympathetic is biased towards the latter. The opposite phenomenon has been referred to as sympatheticotonia.
Neurocardiology is the study of the neurophysiological,neurological and neuroanatomical aspects of cardiology,including especially the neurological origins of cardiac disorders. The effects of stress on the heart are studied in terms of the heart's interactions with both the peripheral nervous system and the central nervous system.
David Alfred Eisner,FRCP (Hon),FMedSci,is British Heart Foundation Professor of Cardiac Physiology at the University of Manchester and editor-in-chief of The Journal of General Physiology (JGP).
Jonathan Solomon Stamler is an English-born American physician and scientist. He is known for his discovery of protein S-nitrosylation,the addition of a nitric oxide (NO) group to cysteine residues in proteins,as a ubiquitous cellular signal to regulate enzymatic activity and other key protein functions in bacteria,plants and animals,and particularly in transporting NO on cysteines in hemoglobin as the third gas in the respiratory cycle.
Autonomic drugs are substances that can either inhibit or enhance the functions of the parasympathetic and sympathetic nervous systems. This type of drug can be used to treat a wide range of diseases an disorders,including glaucoma,asthma,and disorders of the urinary,gastrointestinal and circulatory systems.
John Thompson Shepherd was a British-American cardiologist,medical researcher in cardiovascular physiology,and medical school dean. His research on the regulation of the cardiovascular system included "classic studies on reflex control of the circulation,haemodynamic responses to heat stress and exercise,and mechanisms of vasodilation."
Dario DiFrancesco is a Professor Emeritus (Physiology) at the University of Milano. In 1979,he and collaborators discovered the so-called "funny" current in cardiac pacemaker cells,a new mechanism involved in the generation of cardiac spontaneous activity and autonomic regulation of heart rate. That initiated a new field of research in the heart and brain,where hyperpolarization-activated,cyclic nucleotide-gated (HCN) channels,the molecular components of "funny" channels cloned in the late 90's,are today known to play fundamental roles in health and disease. Clinically relevant exploitation of the properties of "funny" channels has developed a channel blocker with specific heart rate-slowing action,ivabradine,marketed for the therapy of coronary artery disease,heart failure and the symptomatic treatment of chronic stable angina.